Brian E. Mcdowell

Array ( [id] => 18375862 [patent_doc_number] => 20230150943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => CLEAVABLE AGENTS [patent_app_type] => utility [patent_app_number] => 18/149740 [patent_app_country] => US [patent_app_date] => 2023-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418613 [patent_doc_number] => 20230173071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => TREATMENT OF MYOPIA AND OTHER OCULAR CONDITIONS USING SINGLET OXYGEN GENERATED FROM DYES ACTIVATED BY NEAR-INFRARED LIGHT [patent_app_type] => utility [patent_app_number] => 18/082812 [patent_app_country] => US [patent_app_date] => 2022-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18082812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256084 [patent_doc_number] => 12428427 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Methods and compositions for targeting PD-L1 [patent_app_type] => utility [patent_app_number] => 18/066507 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14707 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18066507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626621 [patent_doc_number] => 20230285418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => Methods for the Prevention and Treatment of Hearing Loss [patent_app_type] => utility [patent_app_number] => 18/081951 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18081951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685105 [patent_doc_number] => 11780822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => HDAC inhibitor solid state forms [patent_app_type] => utility [patent_app_number] => 18/080566 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 25 [patent_no_of_words] => 10364 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19354076 [patent_doc_number] => 12054505 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders [patent_app_type] => utility [patent_app_number] => 18/079617 [patent_app_country] => US [patent_app_date] => 2022-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 39013 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 582 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18079617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18318931 [patent_doc_number] => 20230117059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTS [patent_app_type] => utility [patent_app_number] => 18/075513 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18319167 [patent_doc_number] => 20230117295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/075853 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675036 [patent_doc_number] => 20230312587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => PTERIDINONE COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/075270 [patent_app_country] => US [patent_app_date] => 2022-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 142760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075270 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451395 [patent_doc_number] => 20230192673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Compounds [patent_app_type] => utility [patent_app_number] => 17/980186 [patent_app_country] => US [patent_app_date] => 2022-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451395 [patent_doc_number] => 20230192673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Compounds [patent_app_type] => utility [patent_app_number] => 17/980186 [patent_app_country] => US [patent_app_date] => 2022-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451418 [patent_doc_number] => 20230192696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => SPIRO COMPOUNDS AS INHIBITORS OF KRAS [patent_app_type] => utility [patent_app_number] => 18/052347 [patent_app_country] => US [patent_app_date] => 2022-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324784 [patent_doc_number] => 20230122912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors [patent_app_type] => utility [patent_app_number] => 17/968408 [patent_app_country] => US [patent_app_date] => 2022-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18306578 [patent_doc_number] => 20230110478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY [patent_app_type] => utility [patent_app_number] => 17/965843 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 808 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17965843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143900 [patent_doc_number] => 12378227 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy)-N-(5-methylpyrazin-2-yl)benzamide [patent_app_type] => utility [patent_app_number] => 18/688683 [patent_app_country] => US [patent_app_date] => 2022-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 6075 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18688683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391307 [patent_doc_number] => 20230159525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/957584 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 575 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17957584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904100 [patent_doc_number] => 12281096 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone) [patent_app_type] => utility [patent_app_number] => 17/946236 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 17860 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18322126 [patent_doc_number] => 20230120254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => Nitrile-Containing Antiviral Compounds [patent_app_type] => utility [patent_app_number] => 17/932151 [patent_app_country] => US [patent_app_date] => 2022-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479344 [patent_doc_number] => 20240327386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/692791 [patent_app_country] => US [patent_app_date] => 2022-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18692791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518454 [patent_doc_number] => 11708334 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Inhibitors of NLRP3 inflammasome [patent_app_type] => utility [patent_app_number] => 17/930895 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47784 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930895 [rel_patent_id] =>[rel_patent_doc_number] =>)